Company intelligence / Profile preview

Hangzhou Cheetah Cell Therapeutics Co. Ltd.

Hangzhou, Zhejiang, Chinaykrbio.com ↗

Ownership: Private
Development stage: Other

Overview

The company’s lead program, T‑02, uses cord blood-derived NKG2D CAR-NK cells and has entered Phase I clinical trials for recurrent/refractory acute myeloid leukemia and colorectal cancer. Early data focus on safety and dose escalation; efficacy results are not yet published in detail.

Therapeutic areas: Oncology
Modalities: Cell therapyCAR-NK (Chimeric Antigen Receptor Natural Killer cells)
Industry: Biotech

Drug pipeline

2 assets

NKG2D CAR-NK

1 more asset in the full pipeline.

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of the latest available data.

Beyond the preview

Go deeper on Hangzhou Cheetah Cell Therapeutics Co. Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Cheetah Cell Therapeutics Co. Ltd..